Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Calypte Biomedical Corporation (CALY) -- Ignore unavailable to you. Want to Upgrade?

To: DAN WONG who wrote (172)	10/22/1997 2:54:00 PM
From: JanyBlueEyes	Read Replies (2) \| Respond to of 381

PRIVATE PLACEMENT - NEWS - 10-22-97 ALAMEDA, Calif.--(BW HealthWire)--Oct. 22, 1997--Calypte Biomedical Corp. (NASDAQ Small Cap: CALY) today announced the completion of a private placement of common stock which raised over $10 million. Pacific Growth Equities acted as sole placement agent on the offering. Following this transaction, the company has 13.1 million weighted average shares outstanding. "These new funds will allow Calypte to, first, complete the scale-up of manufacturing for our urine-based test for HIV-1," said Jack Davis, president and chief executive officer. "Second, they will allow us to initiate the development of additional urine-based diagnostic tests including the Calypte HIV-1 urine test for Home Collection, and to undertake the clinical trials required for this application." Calypte announced on September 18th that the manufacturer of the Western Blot confirmatory test which is used in conjunction with the Calypte Biomedical HIV-1 urine screening assay had received, from the Food and Drug Administration, a "Review Complete" letter. The "Review Complete" letter indicated that the kit may be marketed once the company has addressed the labeling issues posed in the "Review Complete" letter and the product labeling review process has been completed. Calypte Biomedical Corp. is an Alameda and Berkeley, California based health care company dedicated to the development and commercialization of urine-based diagnostic products and services for HIV-1, sexually transmitted diseases and other chronic illnesses. Statements in this press release that are not historical facts are forward-looking statements.........